HotSpot Therapeutics Completes $65 Million Series B Financing to Advance Pipeline of Novel Allosteric Medicines
Financing Accelerates Development of First-in-Class Therapies with Genetically Validated Mechanisms for Treatment of Autoimmune Diseases, Rare Diseases and Cancer
BOSTON, May 21, 2020 -- (Healthcare Sales & Marketing Network) -- HotSpot Therapeutics, I... Biopharmaceuticals, Venture Capital HotSpot Therapeutics, Macroceutics, SpotFinder, allosteric therapies
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Autoimmune Disease | Cancer | Cancer & Oncology | Genetics | Marketing | Pharmaceuticals | Rare Diseases | Venture Capital